Nautilus Biotechnology (NASDAQ:NAUT – Get Free Report) posted its earnings results on Monday. The company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.02, FiscalAI reports. The firm had revenue of $0.23 million during the quarter, compared to the consensus estimate of $0.21 million.
Nautilus Biotechnology Price Performance
Shares of NASDAQ:NAUT opened at $2.44 on Tuesday. The company has a market capitalization of $310.49 million, a price-to-earnings ratio of -5.42 and a beta of 0.73. The business’s 50-day moving average is $1.42 and its 200-day moving average is $2.09. Nautilus Biotechnology has a 1 year low of $0.84 and a 1 year high of $4.31.
Analyst Ratings Changes
A number of research firms recently commented on NAUT. Weiss Ratings cut shares of Nautilus Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, August 5th. Zacks Research raised Nautilus Biotechnology to a “hold” rating in a research report on Wednesday, September 30th. Roth Capital began coverage on shares of Nautilus Biotechnology in a research note on Tuesday, September 29th. They issued a “buy” rating and a $3.50 target price for the company. Finally, Leerink Partners began coverage on shares of Nautilus Biotechnology in a report on Wednesday, September 9th. They issued an “outperform” rating and a $4.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $3.83.
Get Our Latest Analysis on Nautilus Biotechnology
About Nautilus Biotechnology
Nautilus Biotechnology, Inc is a biotechnology company developing technologies for large-scale protein analysis, also known as proteomics. Its goal is to enable researchers to identify and quantify proteins more comprehensively, helping advance drug discovery, biological research and the development of precision medicine.
The company’s principal offering is the Nautilus Proteome Analysis Platform, an integrated system that combines specialized instrumentation, consumables and software.
Recommended Stories
- Five stocks we like better than Nautilus Biotechnology
- AST SpaceMobile Faces Launch Risks as SpaceX Raises the Competitive Stakes
- GXO Logistics Is Turning Warehouse Robots Into a Growth Strategy
- A Solid Margin Story Means the Sell-Off in DECK May Be Overdone
- Verizon’s Q3 Results Show Why SpaceX’s Spectrum Grab Isn’t a Major Threat
Receive News & Ratings for Nautilus Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nautilus Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
